## Exploring microtubule-targeting-agent - tumor-immune-response interaction on clinical response in breast cancer.
Version 1.0.0 

Code associated with the following research project.

# Microtubule targeting agents influence the clinical benefit of immune response in early breast cancer

Vinu Jose $^{1}$, David Venet $^{1}$, Francoise Rothe $^{1}$, Samira Majjaj $^{1}$, Delphine Vincent $^{1}$, Laurence Buisseret $^{1,2}$, Roberto Salgado $^{1,3,4}$, Nicolas Sirtaine $^{5,6}$, Stefan Michiels $^{1,7}$, Sherene Loi $^{1,4,8}$, Heikki Joensuu $^{9}$, Christos Sotiriou $^{1,2}$

1. JC Heuson Breast Cancer Translational Research Laboratory (BCTL), Institut Jules Bordet - Université Libre de Bruxelles, 90 Rue Meylemeersch, 1070 Anderlecht, Belgium.
2. Department of Medical Oncology, Institut Jules Bordet - Université Libre de Bruxelles, 90 Rue Meylemeersch, 1070 Anderlecht, Belgium
3. Department of Pathology, GZA-ZNA Hospitals, Sint-Vincentiusstraat 20, 2018 Antwerp, Belgium.
4. Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
5. Department of Pathology, Institut Jules Bordet - Université Libre de Bruxelles, 90 Rue Meylemeersch, 1070 Anderlecht, Belgium.
6. Deptartment of Pathology, Unité Jolimont asbl, Rue Ferrer 159, 7100 Haine-Saint-Paul, Belgium.
7. Service de Biostatistique et d’Epidémiologie, Gustave Roussy, Oncostat U1018, Inserm, Paris-Saclay University, labeled Ligue Contre le Cancer, Villejuif, France.
8. Sir Peter MacCallum Cancer Department of Oncology, University of Melbourne, Melbourne, VIC, Australia
9. Helsinki University Hospital and University of Helsinki, Helsinki, Finland
    
## Abstract

*PURPOSE*: Immune response to tumors is  associated with clinical benefits in breast cancer. Preclinically, microtubule dynamics affect the cytotoxic potential of the immune system. We investigate the impact of microtubule targeting agents (MTA)
 on immune response’s clinical benefit in early breast cancer.

*METHODS*: We used the gene expression dataset associated with the randomized
 FinHER adjuvant phase III trial, which compared Docetaxel (stabilizing MTA) to Vinorelbine (destabilizing MTA), and an integrated non-randomized GEO neoadjuvant dataset with regimens containing stabilizing MTA or without any MTA. Cox/logistic interaction models assessed the interaction between MTAs and immune response on clinical benefit. Immune response was measured using histopathology (TIL-H&E), gene module scores, and immune cell-type estimation methods.

*RESULTS*: MTA and immune responses seem to interact in breast cancer, particularly in TNBC, affecting patient survival. In the randomized FinHER adjuvant TNBC setting, a unit increase in interferon score is associated with a death hazard-ratio  of 10.97 (95% confidence interval, 0.79 to 151.78) in the Docetaxel arm (n=60), and a death  hazard-ratio of 0.16 (0.03 to 0.97) in the Vinorelbine arm (n=60), P-interaction = 0.008 (FDR-adjusted, 0.039). In the non-randomized neoadjuvant TNBC setting, a unit increase in interferon score is associated with a pathological-complete-response (pCR) odds-ratio of 1.3 (0.6 to 3.1) in stabilizing MTA regimens (n=293), and a pCR  odds-ratio of 46.8 (3.9 to 557.7) in non-MTA regimens (n=83), P-interaction = 0.004 (FDR-adjusted, 0.032).

*CONCLUSION*: MTAs influence the clinical benefit of immune response in breast cancer. However, the limited sample size warrants additional analyses.

